The First Affiliated Hospital of Nanchang University
Comparison of Short- and Long-term Outcomes Between Robotic and Laparoscopic Hemicolectomy of Right Colon Cancer : A Multicenter Propensity Score Matching Analysis
- Conditions
- Robotic Surgical ProceduresRight Colon TumorsCancerLaparoscopic Abdominal Surgery
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Target Recruit Count
- 4000
- Registration Number
- NCT07029464
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed/RefractoryMultiple Myeloma
- Interventions
- Biological: BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-05-31
- Target Recruit Count
- 12
- Registration Number
- NCT06999031
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751966
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
- Conditions
- Advanced NSCLC
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06752057
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
- Conditions
- Advanced NSCLC
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751901
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-loaded DC Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- Combination Product: Conventional second-line therapy
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751940
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
- Conditions
- Advanced NSCLC
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06752044
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
- Conditions
- Advanced NSCLC
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751849
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- Combination Product: Conventional second-line therapy
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751914
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- Combination Product: Conventional third-line therapy
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751953
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China